Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study

J Tabernero; E Van Cutsem; Yung Jue Bang; Charles Fuchs; L Wyrwicz; KW Lee; I Kudaba; M Garrido; HCC Chung; HR Castro-Salguero; W Mansoor; MI Braghiroli; E Goekkurt; J Chao; ZA Wainberg; U Kher; S Shah; S. Peter Kang; Kohei Shitara

doi:10.1200/JCO.2019.37.18_suppl.LBA4007

Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study

J Tabernero
, E Van Cutsem
, Yung Jue Bang
, Charles Fuchs
, L Wyrwicz
, KW Lee
, I Kudaba
, M Garrido
, HCC Chung
, HR Castro-Salguero
, W Mansoor
, MI Braghiroli
, E Goekkurt
, J Chao
, ZA Wainberg
, U Kher
, S Shah
, S. Peter Kang
, Kohei Shitara

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Article number	LBA4007
Journal	Journal of Clinical Oncology
Volume	37
Issue number	18, Suppl.
DOIs	https://doi.org/10.1200/JCO.2019.37.18_suppl.LBA4007
Publication status	Published - Jun 2019
Externally published	Yes
Event	Annual Meeting of the American Society of Clinical Oncology - Chicago, United States Duration: 31 May 2019 → 4 Jun 2019 https://dctd.cancer.gov/NewsEvents/asco2019.htm

Field of Science*

3.2 Clinical medicine

Publication Type*

3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

Access to Document

10.1200/JCO.2019.37.18_suppl.LBA4007

Cite this

Tabernero, J., Van Cutsem, E., Bang, Y. J., Fuchs, C., Wyrwicz, L., Lee, KW., Kudaba, I., Garrido, M., Chung, HCC., Castro-Salguero, HR., Mansoor, W., Braghiroli, MI., Goekkurt, E., Chao, J., Wainberg, ZA., Kher, U., Shah, S., Kang, S. P., & Shitara, K. (2019). Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study. Journal of Clinical Oncology, 37(18, Suppl.), Article LBA4007. https://doi.org/10.1200/JCO.2019.37.18_suppl.LBA4007

@article{02d135e34aeb41d5bf81184b1ff750f4,

title = "Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study",

author = "J Tabernero and \{Van Cutsem\}, E and Bang, \{Yung Jue\} and Charles Fuchs and L Wyrwicz and KW Lee and I Kudaba and M Garrido and HCC Chung and HR Castro-Salguero and W Mansoor and MI Braghiroli and E Goekkurt and J Chao and ZA Wainberg and U Kher and S Shah and Kang, \{S. Peter\} and Kohei Shitara",

year = "2019",

month = jun,

doi = "10.1200/JCO.2019.37.18\_suppl.LBA4007",

language = "English",

volume = "37",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

number = "18, Suppl.",

note = "Annual Meeting of the American Society of Clinical Oncology, ASCO ; Conference date: 31-05-2019 Through 04-06-2019",

url = "https://dctd.cancer.gov/NewsEvents/asco2019.htm",

}

Tabernero, J, Van Cutsem, E, Bang, YJ, Fuchs, C, Wyrwicz, L, Lee, KW, Kudaba, I, Garrido, M, Chung, HCC, Castro-Salguero, HR, Mansoor, W, Braghiroli, MI, Goekkurt, E, Chao, J, Wainberg, ZA, Kher, U, Shah, S, Kang, SP & Shitara, K 2019, 'Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study', Journal of Clinical Oncology, vol. 37, no. 18, Suppl., LBA4007. https://doi.org/10.1200/JCO.2019.37.18_suppl.LBA4007

Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study. / Tabernero, J; Van Cutsem, E; Bang, Yung Jue et al.
In: Journal of Clinical Oncology, Vol. 37, No. 18, Suppl., LBA4007, 06.2019.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma

T2 - Annual Meeting of the American Society of Clinical Oncology

AU - Tabernero, J

AU - Van Cutsem, E

AU - Bang, Yung Jue

AU - Fuchs, Charles

AU - Wyrwicz, L

AU - Lee, KW

AU - Kudaba, I

AU - Garrido, M

AU - Chung, HCC

AU - Castro-Salguero, HR

AU - Mansoor, W

AU - Braghiroli, MI

AU - Goekkurt, E

AU - Chao, J

AU - Wainberg, ZA

AU - Kher, U

AU - Shah, S

AU - Kang, S. Peter

AU - Shitara, Kohei

PY - 2019/6

Y1 - 2019/6

UR - https://www-webofscience-com.db.rsu.lv/wos/alldb/full-record/WOS:000489109800011

U2 - 10.1200/JCO.2019.37.18_suppl.LBA4007

DO - 10.1200/JCO.2019.37.18_suppl.LBA4007

M3 - Meeting Abstract

SN - 0732-183X

VL - 37

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 18, Suppl.

M1 - LBA4007

Y2 - 31 May 2019 through 4 June 2019

ER -

Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study

Field of Science*

Publication Type*

Access to Document

Other files and links

Cite this